Condition

Relapsed Cancer clinical trials and research

• 12Clinical trials
• 11Countries

Newest Relapsed Cancer clinical trials

All recruiting trials (12)

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• Roginolisib with venetoclax and rituximab for relapsed or refractory CLL

  This trial will test whether adding roginolisib to the standard venetoclax plus rituximab treatment helps people with relapsed or refractory CLL get deeper and longer remissions.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06644183

• Investigating a new cancer treatment for relapsed or refractory B-cell malignancies

  This study is testing a new cancer drug called BGB-16673 combined with other treatments to see if it can help people with tough-to-treat B-cell cancers feel better.

  Recruiting at 49 sites Phase 1/2 BeOne Medicines · Phoenix, Arizona and 48 other locations · NCT06634589

• Metabolic, transcriptomic, and proteomic profiling of relapsed glioblastoma

  This project will see if comparing genes, proteins, and metabolism in original versus relapsed tumors can reveal markers or targets for people with relapsed IDH‑wildtype glioblastoma who had repeat surgery at CHU de Bordeaux.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT06430424

• Outpatient teclistamab treatment plan for relapsed or refractory multiple myeloma

  This pilot will try giving teclistamab to adults with relapsed or refractory multiple myeloma in an outpatient clinic to see if it can be delivered safely and practically while measuring effects on caregivers.

  Recruiting Phase 4 University Health Network, Toronto · Toronto, Ontario · NCT06251076

• Isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone combination for relapsed/refractory multiple myeloma

  This trial tries the combination of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone to see if it can reduce multiple myeloma in adults whose disease has returned or stopped responding to prior treatment.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT05922501

• Combination therapy for relapsed large cell lymphoma using epcoritamab and chemotherapy

  This study is testing a new combination of treatments for people with relapsed large cell lymphoma to see if it helps them respond better after previous therapies.

  Recruiting at 4 sites Phase 2 Hoosier Cancer Research Network · Indianapolis, Indiana and 3 other locations · NCT05852717

• Combining zanubrutinib and pemetrexed for treating relapsed or refractory CNS lymphomas

  This study is testing if combining two medications, zanubrutinib and pemetrexed, can help people with relapsed or stubborn central nervous system lymphomas feel better and live longer.

  Recruiting Phase 2 Baptist Health South Florida · Miami, Florida · NCT05681195

• Precision medicine for children with cancer

  This study is testing if personalized medicine can improve treatment and outcomes for children with different types of cancer in Australia and New Zealand.

  Recruiting at 10 sites Australian & New Zealand Children's Haematology/Oncology Group · Adelaide and 10 other locations · NCT05504772

• Allogeneic CAR T-cell therapy for advanced cancers

  This study is testing a new type of immune cell therapy for people with advanced cancers to see if it can safely target and attack their tumors better than traditional treatments.

  Recruiting Phase 1 CytoMed Therapeutics Pte Ltd · Singapore · NCT05302037

• Combining pembrolizumab and bendamustine for treating relapsed Hodgkin lymphoma

  This study is testing whether combining two drugs, pembrolizumab and bendamustine, can help people with relapsed Hodgkin lymphoma feel better and improve their treatment outcomes.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT04510636

• Combination therapy for recurrent primary central nervous system lymphoma

  This study is testing a new combination of three medications to see if it can help people with recurrent primary central nervous system lymphoma feel better after their previous treatments didn't work.

  Recruiting at 3 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 3 other locations · NCT04421560

Related topics

Quick answers

How many Relapsed Cancer clinical trials are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 11 countries. The most sites are in United States (7 trials), Canada (2 trials), Australia (2 trials), New Zealand (2 trials), Singapore (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1/2: 4, Phase 4: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →